The tumor microenvironment: Part 1

Immunotherapy

Volumn 3, Issue 11, 2011, Pages 1367-1384

  Leibovici, Judith ^a   Itzhaki, Orit ^a   Huszar, Monica ^a   Sinai, Judith ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

immune components; immune evasion; nonimmune components; tumor microenvironment; tumor progression

Indexed keywords

ADENOSINE; AMG 714; ARGINASE; CHEMOKINE RECEPTOR CXCR4; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 12; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 4; MATRILYSIN; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; PROTEIN P53; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; TIE RECEPTOR; TOSYLARGININE METHYL ESTER; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ADIPOCYTE; BLOOD VESSEL; BONE MARROW CELL; CELL COMPOSITION; CELL LINEAGE; CELL PROLIFERATION; DENDRITIC CELL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; HUMAN; HYPOXIA; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LYMPH VESSEL; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPHIL; NONHUMAN; PERICYTE; PH; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH;

ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; IMMUNE EVASION; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 80755142757     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.111     Document Type: Review

References (165)

1. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis. Rev. 8(2), 98-101 (1989).
2. Witz IP. The tumor microenvironment: the making of a paradigm. Cancer Microenviron. 2(Suppl. 1), 9-17 (2009).
3. Park CC, Bissell MJ, Barcellos Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol. Med. Today 6(8), 324-329 (2000). (Pubitemid 30619340)
4. Ronnov Jessen L, Bissell MJ. Breast cancer by proxy: can the microenvironment be both the cause and consequence? Trends Mol. Med. 15(1), 5-13 (2009).
5. Sager R. Expression genetics in cancer: shifting the focus from DNA to RNA. Proc. Natl Acad. Sci. USA 94(3), 952-955 (1997). (Pubitemid 27074428)
6. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4(1), 71-78 (2004). (Pubitemid 38082155)
7. Egeblad M, Littlepage LE, Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harb. Symp. Quant. Biol. 70, 383-388 (2005). (Pubitemid 44124893)
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000). (Pubitemid 30046295)
9. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7), 1073-1081 (2009).
10. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316(8), 1324-1331 (2010).
11. + T cells. World J. Surg. 19(3), 352-358 (1995).
12. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58(16), 3491-3494 (1998). (Pubitemid 28376536)
13. Galon J, Costes A, Sanchez Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006). (Pubitemid 44498003)
14. Clark WH Jr, Elder DE, Guerry DT et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81(24), 1893-1904 (1989). (Pubitemid 20026075)
15. Clemente CG, Mihm MC JR, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7), 1303-1310 (1996). (Pubitemid 26102328)
16. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45), 5904-5912 (2008).
17. Pages F, Galon J, Dieu-Nosjean MC et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29 (8), 1093-1102 (2010).
18. Mlecnik B, Tosolini M, Kirilovsky A et al. Histologic-based prognostic factors of colorectal cancers are associated with the state of local immune reaction. J. Clin. Oncol. 29 (6), 610-618 (2011).
19. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (3), 203-213 (2003). (Pubitemid 36077915)
20. Kandalaft LE, Powell DJ, Sing N, Coukos G. Immunotherapy of ovarian cancer: what's next? J. Clin. Oncol. 29 (7), 925-933 (2011).
21. Sappino AP, Schurch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab. Invest. 63(2), 144-161 (1990). (Pubitemid 20262130)
22. Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt SJ. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N. Engl. J. Med. 340(6), 430-436 (1999). (Pubitemid 29084774)
23. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int. J. Dev. Biol. 48(5-6), 509-517 (2004). (Pubitemid 39360401)
24. Gonda TA, Varro A, Wang TC, Tycko B. Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin. Cell Dev. Biol. 21(1), 2-10 (2010).
25. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Curr. Opin Genet. Dev. 19(1), 67-73 (2009).
26. Kraman M, Bambrough PJ, Arnold JN et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein a. Science 330 (6005), 827-830 (2010).
27. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116(7), 1955-1962 (2006). (Pubitemid 44033319)
28. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF kB-dependent manner. Cancer Cell 17(2),135-147 (2010).
29. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 65(19), 8887-8895 (2005). (Pubitemid 41377378)
30. Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF 1/CXCL12 secretion. Cell 121(3), 335-348 (2005). (Pubitemid 40692295)
31. Augsten M, Hagglof C, Olsson E et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc. Natl Acad Sci. USA 106(9), 3414-3419 (2009).
32. Wu Y, Li YY, Matsushima K, Baba T, Mukaida N. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J. Immunol. 181(9), 6384-6393 (2008).
33. Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14(5), 518-527 (2008). (Pubitemid 351655218)
34. Patocs A, Zhang L, Xu Y et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med. 357(25), 2543-2551 (2007). (Pubitemid 350294221)
35. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. 32(3), 355-357 (2002).
36. Campbell IG, Qiu W, Polyak K, Haviv I. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med. 358(15), 1634-1635 (2008). (Pubitemid 351519837)
37. Dudley AC, Shih SC, Cliffe AR, Hida K, Klagsbrun M. Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br. J. Cancer 99(1), 118-125 (2008). (Pubitemid 351920247)
38. Hawsawi NM, Ghebeh H, Hendrayani SF et al. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res. 68(8), 2717-2725 (2008). (Pubitemid 351556269)
39. Bar J, Feniger Barish R, Lukashchuk N et al. Cancer cells suppress p53 in adjacent fibroblasts. Oncogene 28(6), 933-936 (2009).
40. Celis JE, Moreira JM, Cabezon T et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics 4(4), 492-522 (2005).
41. Zyromski NJ, Mathur A, Pitt HA et al. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery 146(2), 258-263 (2009).
42. Behan JW, Yun JP, Proektor MP et al. Adipocytes impair leukemia treatment in mice. Cancer Res. 69(19), 7867-7874 (2009).
43. Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M. Extracellular matrix: a matter of life and death. Connect Tissue Res. 49(3), 203-206 (2008).
44. Declerck YA, Mercurio AM, Stack MS et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am. J. Pathol. 164(4), 1131-1139 (2004). (Pubitemid 38387779)
45. Gieni RS, Hendzel MJ. Mechanotransduction from the ECM to the genome: are the pieces now in place? J. Cell Biochem. 104(6), 1964-1987 (2008).
46. Vincent T, Mechti N. Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leuk. Lymphoma. 46(6), 803-811 (2005). (Pubitemid 40959669)
47. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin. Sci. (Lond.) 102(4), 417-424 (2002). (Pubitemid 34275794)
48. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer. 10(1), 9-22 (2010).
49. Stallings-Mann M, Radisky D. Matrix metalloproteinase-induced malignancy in mammary epithelial cells. Cells Tissues Organs 185(1-3), 104-110 (2007). (Pubitemid 46956850)
50. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol. Cancer Res. 1(7), 485-499 (2003). (Pubitemid 36577045)
51. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J. Potential prognostic and therapeutic roles for cytokines in breast cancer (review).Oncol. Rep. 15(1), 179-185 (2006).
52. Westwood JA, Berry LJ, Wang LXJ et al. Enhancing adoptive immunotherapy of cancer. Exp. Opin Biol. Ther. 10 (4), 531-545 (2010).
53. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr. Drug Targets 11(9), 1133-1146 (2010).
54. Kane A, Yang I. Interferon g in brain tumor immunotherapy. Neurosurg. Clin. N. Am. 21(1), 77-86 (2010).
55. Egilmez NK, Kilinc MO, Gu T, Coway TF. Controlled-release particulate cytokine adjuvants for cancer therapy. Endocr. Metab. Immune Disord. Drug Targets 7(4), 266-270 (2007).
56. Weiss JM, Subleski JJ, Wiggington JM, Wiltrout RH. Immunotherapy of cancer by IL 12-based cytokine combinations. Exp. Opin Biol. Ther. 7(11), 1705-1721 (2007). (Pubitemid 350157496)
57. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 16(3), 133-144 (2010).
58. Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv. Drug Deliv. Rev. 58(8), 962-974 (2006). (Pubitemid 44780906)
59. Sing S, Sadanandam A, Sing RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metast. Rev. 26(3-4), 453-467 (2007). (Pubitemid 350115099)
60. Raman D, Baugher PJ Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 256 (2), 137-165 (2007). (Pubitemid 47418345)
61. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin. Exp. Metast. 25 (4), 345-356 (2007).
62. Soria G, Ben Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267(2), 271-285 (2008).
63. Ben-Baruch A. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion. Cell Adh. Migr. 3(4), 328-333 (2009).
64. Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J. Leukoc. Biol. 89(1), 31-39 (2011).
65. Zhang J, Lu Y, Pienta K. Multiple roles of of chemokines (C-C motif ) ligand 2 in promoting prostate cancer growth. J. Natl Cancer Inst. 102(8), 522-528 (2010).
66. Hirbe AC, Morgan EA, Welbaecher KN. The CXCR4/SDF chemokine axis: a potential therapeutic target for bone metastasis? Curr. Pharm. Des. 16(11), 1284-1290 (2010).
67. Zhang J, Patel L and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21(1), 41-48 (2010).
68. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J. Immunother. 29(3), 233-240 (2006). (Pubitemid 44297291)
69. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol. 24(6), 335-342 (2003).
70. Frey AB, Monu N. Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J. Leukoc. Biol. 79(4), 652-662 (2006). (Pubitemid 44835597)
71. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 7, 10 (2007).
72. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007). (Pubitemid 46697910)
73. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 27(45), 5894-5903 (2008).
74. Siemens DR, Hu N, Sheikhi AK et al. Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res. 68(12), 4746-4753 (2008).
75. De Baetselier P, Katzav S, Gorelik E, Feldman M, Segal S. Differential expression of H 2 gene products in tumour cells in associated with their metastatogenic properties. Nature 288(5787), 179-181 (1980). (Pubitemid 11212608)
76. Huszar M, Tzur-Lerman A, Eisenbach L, Leibovici J. Changes in MHC antigen expression during tumor progression in the AKR lymphoma. Israel J. Med. Sci. 11, 859-860 (1994).
77. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315(26), 1650-1659 (1986). (Pubitemid 17052899)
78. Whiteside TL, Vujanovic NL, Herberman RB. Natural killer cells and tumor therapy. Curr. Top. Microbiol. Immunol. 230, 221-244 (1998). (Pubitemid 28183725)
79. Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK cell-activating ligand changes in malignant cells: current challenges and future directions. Adv. Cancer Res. 93, 189-234 (2005). (Pubitemid 41557276)
80. Fidler IJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim. Biophys. Acta 948(2), 151-173 (1988). (Pubitemid 18263873)
81. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196(3), 254-265 (2002). (Pubitemid 34189413)
82. Puig-Kroger A, Sierra-Filardi E, Dominguez Soto A et al. Folate receptor b is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 69(24), 9395-9403 (2009).
83. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5(12), 953-964 (2005). (Pubitemid 41746764)
84. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23(11), 549-555 (2002). (Pubitemid 35223554)
85. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3(1), 23-35 (2003). (Pubitemid 37328697)
86. Verreck FA, De Boer T, Langenberg DM et al. Human IL 23-producing type 1 macrophages promote but IL 10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc. Natl Acad. Sci. USA 101(13), 4560-4565 (2004). (Pubitemid 38437450)
87. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8(7), 533-544 (2008). (Pubitemid 351913679)
88. Biswas SK, Gangi L, Paul S et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF kB and enhanced IRF 3/STAT1 activation).Blood 107(5), 2112-2122 (2006). (Pubitemid 43289397)
89. Gocheva V, Wang HW, Gadea BB et al. IL 4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 24(3), 241-255 (2010).
90. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front. Biosci. 13, 453-461 (2008). (Pubitemid 351599757)
91. Mantovani A. La mala educacion of tumor-associated macrophages: diverse pathways and new players. Cancer Cell 17(2), 111-112 (2010).
92. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117(5), 1155-1166 (2007). (Pubitemid 46718400)
93. Terabe M, Matsui S, Park JM et al. Transforming growth factor b production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198(11), 1741-1752 (2003). (Pubitemid 37494166)
94. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. Adv. Exp. Med. Biol. 601, 213-223 (2007).
95. Yang L, Debusk LM, Fukuda K et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6(4), 409-421 (2004). (Pubitemid 39361441)
96. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit. Rev. Oncol. Hematol. 77(1), 12-19 (2010).
97. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180-191 (2008). (Pubitemid 351430370)
98. De Palma M, Venneri MA, Galli R et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3), 211-226 (2005). (Pubitemid 41317592)
99. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 28(12), 519-524 (2007).
100. Coffelt SB, Tal AO, Scholz A et al. Angiopoietin 2 regulates gene expression in TIE-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 70(13), 5270-5280 (2010).
101. De Palma M Naldini L. Tie2-expressing (TEM).Novel targets and vehicles of anticancer therapy? Biochim. Biophys. Acta 1796(1) 5-10 (2009).
102. Fridlender ZG, Sun J, Kim S et al. Polarization of tumor-associated neutrophil phenotype by TGF β-b: "N1" versus "N2" TAN. Cancer Cell 16(3), 183-194 (2009).
103. Rivoltini L, Carrabba M, Huber V et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev. 188, 97-113 (2002). (Pubitemid 35398868)
104. Risin D, Kleinerman ES, Umezu Y, Pizzini RP, Balch CM, Pellis NR. Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide- phosphatidylethanolamine. Cancer Immunol. Immunother. 40(1), 57-64 (1995).
105. Liu K, Caldwell SA, Abrams SI. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN g-regulated gene expression. Cancer Res. 65(10), 4376-4388 (2005). (Pubitemid 40775677)
106. Wang HY, Wang RF. Regulatory T cells and cancer. Curr. Opin Immunol. 19(2), 217-223 (2007). (Pubitemid 46356965)
107. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol 6(4), 295-307 (2006).
108. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 67(18), 8865-8873 (2007). (Pubitemid 47437463)
109. +CD25highFoxp3+ T cells secreting interleukin 10 and transforming growth factor b1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 13(15 Pt 1), 4345-4354 (2007). (Pubitemid 47219698)
110. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169(5), 2756-2761 (2002). (Pubitemid 34921025)
111. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004). (Pubitemid 39273735)
112. Beyer M, Schultze JL. Immunoregulatory T cells: role and potential as a target in malignancy. Curr. Oncol. Rep. 10(2), 130-136 (2008). (Pubitemid 351395473)
113. Cubillos Ruiz JR, Rutkowski M, Conejo Garcia JR. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 9(2), 260-268 (2010).
114. Mukherjee P, Ginardi AR, Madsen CS et al. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj. J. 18(11-12), 931-942 (2001). (Pubitemid 36315058)
115. + regulatory T cells. J. Immunol. 172 (10), 5986-5993 (2004). (Pubitemid 38621199)
116. Mocellin S, Panelli MC, Wang C, Nagorsen D, Marincola FM. The dual role of IL 10. Trends Immunol. 24(1), 36-43 (2003).
117. Zheng LM, Oscius DM, Garaud F et al. Interleukin 10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. 184(2) 579-584 (1996). (Pubitemid 26324111)
118. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J. Natl. Cancer Inst. 88 (8), 536-541 (1996). (Pubitemid 26118724)
119. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin 10 and the interleukin 10 receptor. Annu. Rev. Immunol. 19, 683-765 (2001).
120. Enk AH Jonuleit H, Salog J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer 73(3), 309-316 (1997). (Pubitemid 27508890)
121. Yue FY, Dummer R, Geertsen R et al. Interleukin 10 is a growth factor for human melanoma cells and down-regulates HLA class I, HLA class II and ICAM I molecules. Int. J. Cancer 71(4), 630-637 (1997).
122. Mocellin S, Marincola FM, Young HA. Interleukin 10 and the immune response agaist cancer: a counterpoint: J. Leuk. Biol. 78(5), 1043-1051 (2005). (Pubitemid 41572467)
123. Jovasevic VM, Gorelik M, Bluestone JA, Mokyr MB. Importance of IL 10 for CTLA 4-mediated inhibition of tumor-eradicating immunity. J. Immunol. 172(3), 1449-1454 (2004). (Pubitemid 38116787)
124. Vicari AP, Chiodoni C, Vaure C. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196(4) 541-549 (2002).
125. Kim BG, Joo HG, Chung IS, Chung HY, Woo HJ, Yun VS. Inhibition of interleukin 10 (IL 10) production from MOPC 315 tumor cells by IL 10 antisense oligodeoxynucleotides enhances cell-mediated immune response. Cancer Immunol. Immunother. 49(8), 433-440 (2000).
126. Luboshits G, Shina S, Kaplan O et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59(18), 4681-4687 (1999). (Pubitemid 29428976)
127. Saraiva M, O'Garra A. The regulation of IL 10 production by immune cells. Nat. Rev. Immunol. 10(3), 170-181 (2010).
128. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor b signaling in T cells. Nat. Med. 7(10), 1118-1122 (2001). (Pubitemid 33010019)
129. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor b regulation of immune responses. Annu. Rev. Immunol. 24, 99-146 (2006).
130. Korpal M, Kang Y. Targeting the transforming growth factor b signalling pathway in metastatic cancer. Eur. J. Cancer 46(7), 1232-1240 (2010).
131. Kortylewski M, Yu H. STAT3 as a potential target for cancer immunotherapy. J. Immunother. 30(2), 131-139 (2007). (Pubitemid 46667794)
132. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4(2), 97-105 (2004). (Pubitemid 38198738)
133. Benson DM JR, Bakan CE, Mishra A et al. The PD 1/PD L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT 011, a novel monoclonal anti-PD 1 antibody. Blood 116(13), 2286-2294 (2010).
134. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 28(3), 682-688 (2010).
135. Nomi T, Sho M, Akahori T et al. Clinical significance and therapeutic potential of the programmed death 1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13(7), 2151-2157 (2007). (Pubitemid 46649885)
136. Hino R, Kabashima K, Kato Y et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7), 1757-1766 (2010).
137. Ghebeh H, Mohammed S, Al-Omair A et al. The B7 H1 (PD L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8(3), 190-198 (2006). (Pubitemid 43671234)
138. Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr. Opin Investig. Drugs 11(12), 1354-1359 (2010).
139. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117(5), 1147-1154 (2007).
140. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380), 1191-1193 (1998). (Pubitemid 28406294)
141. Zamanakou M, Germenis AE, Karanikas V. Tumor immune escape mediated by indoleamine 2,3 dioxygenase. Immunol. Lett. 111(2), 69-75 (2007). (Pubitemid 47212491)
142. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3 dioxygenase. Nat. Med. 9(10), 1269-1274 (2003). (Pubitemid 37279849)
143. Muller AJ, Duhadaway JB, Donover PS, Sutanto Ward E, Prendergast GC. Inhibition of indoleamine 2,3 dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11(3), 312-319 (2005). (Pubitemid 40460560)
144. Aryee DN, Niedan S, Kauer M et al. Hypoxia modulates EWS FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res. 70(10), 4015-4023 (2010).
145. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin. Cancer Res. 14(19), 5947-5952 (2008).
146. Hoskin DW, Mader JS, Furlong S, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (review).Int. J. Oncol. 32(3), 527-535 (2008). (Pubitemid 351330458)
147. Fischer B, Muller B, Fisch P, Kreutz W. An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy. J. Immunother. 23(2), 196-207 (2000). (Pubitemid 30165169)
148. O'Brien J, Lyons T, Monks J et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am. J. Pathol. 176(3), 1241-1255 (2010).
149. Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J. Immunol. 184(2), 702-712 (2010).
150. Leibovici J, Hoenig S. Lysis and growth stimulation of a murine melanoma determined by density of macrophage populations. Anticancer Res. 5(5), 545-551 (1985).
151. Ojalvo LS, King W, Cox D, Pollard JW. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am. J. Pathol. 174(3), 1048-1064 (2009).
152. Casal C, Torres-Collado AX, Plaza Calonge Mdel C et al. ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells. Cancer Res. 70(11), 4676-4686 (2010).
153. Masuda M, Suzui M, Yasumatu R et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 62(12), 3351-3355 (2002). (Pubitemid 34651376)
154. Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1), 105-115 (1999). (Pubitemid 29077388)
155. Niu G, Wright KL, Huang M et al. Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13), 2000-2008 (2002). (Pubitemid 34270888)
156. Xie TX, Wei D, Liu M et al. STAT3 activation regulates the expression of matrix metalloproteinase 2 and tumor invasion and metastasis. Oncogene 23(20), 3550-3560 (2004). (Pubitemid 38658421)
157. Niu G, Wright KL, MA Y et al. Role of STAT3 in regulating p53 expression and function. Mol. Cell. Biol. 25(17), 7432-7440 (2005). (Pubitemid 41170107)
158. Loomans CJ, Wan H, de Crom R et al. Angiogenic murine endothelial progenitor cells are derived from a myeloid bone marrow fraction and can be identified by endothelial NO synthase expression. Arterioscl. Thromb. Vasc. Biol. 26(8), 1760-1767 (2006). (Pubitemid 44305329)
159. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R Ruegg C, Christofori G. Myeloid cells contribute to tumor lymphangiogenesis. PLoS ONE 4, E7067, (2009).
160. Sebzda E, Heebard C, Sweeney S et al. Syk and Slp 76 mutant mice reveal a cell-autonomous hematopietic cell contribution to vascular development. Dev. Cell. 11(3), 349-361 (2006). (Pubitemid 44283944)
161. Maruyama K, Ii M, Cursiefen C et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Invest. 115(9), 2363-2372 (2005). (Pubitemid 41266198)
162. Maruyama K, Asai J, Ii M et al. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am. J. Pathol. 170(4), 1178-1191 (2007).
163. Kerjaschki D Huttari N, Raab I et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat. Med. 12 (2), 230-234 (2006). (Pubitemid 43214751)
164. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promoting. Science 331(6024), 1565-1570 (2011).
165. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).